Advertisement
UK markets closed

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • FTSE 250

    19,601.98
    -117.39 (-0.60%)
     

  • AIM

    753.12
    -1.57 (-0.21%)
     

  • GBP/EUR

    1.1653
    +0.0008 (+0.07%)
     

  • GBP/USD

    1.2493
    +0.0030 (+0.24%)
     

  • Bitcoin GBP

    51,343.36
    -559.84 (-1.08%)
     

  • CMC Crypto 200

    1,387.46
    +4.89 (+0.35%)
     

  • S&P 500

    5,016.90
    -54.73 (-1.08%)
     

  • DOW

    37,889.04
    -571.88 (-1.49%)
     

  • CRUDE OIL

    82.52
    -0.29 (-0.35%)
     

  • GOLD FUTURES

    2,341.10
    +2.70 (+0.12%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • CAC 40

    8,016.65
    -75.21 (-0.93%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

CORRECTED-Gilead begins testing inhalable form of remdesivir for COVID-19

Reuters
Updated ·1-min read

(Corrects spelling of remdesivir in headline)

July 8 (Reuters) - Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.

The company said the trial, which will enroll about 60 healthy Americans aged between 18 and 45, will test the drug particularly in those cases where the disease has not progressed to require hospitalization. (https://bit.ly/38G3Zup)

Gilead also plans to start additional clinical trials to evaluate remdesivir when used in combination with anti-inflammatory medicines. (Reporting by Dania Nadeem in Bengaluru; Editing by Shounak Dasgupta)